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Abstract 
Use of direct-to-consumer (DTC) advertising by pharmaceutical manufacturers has 
skyrocketed in the past few decades as patients demand more information on drugs and 
the FDA has gotten more relaxed in its regulation of such marketing. In particular, 
television advertisements for prescription drugs for chronic conditions have dramatically 
increased. This paper will analyze the use of DTC advertising for prescription drugs for 
Alzheimer’s disease, a debilitating disease which can last for more than a decade before it 
leads to death. The paper will start with a history of DTC advertising and the FDA’s 
regulation of such advertisements. It will then proceed to analyze issues of DTC 
advertising which are particularly pertinent for Alzheimer’s disease, with an in-depth 
look at Aricept, one FDA-approved drug for Alzheimer’s. The paper will conclude with 
suggestions for further studies in the area and a number of proposals for reform. 
 1 
 
I. History of Regulation of Direct-to-Consumer Advertising 
Pharmaceutical companies traditionally advertised only to physicians and other medical 
professionals.
1 This was because physicians used to be the sole decision-makers when it came to 
medical treatment.
2 Since the 1990s, these companies have increasingly advertised directly to 
consumers through newspaper, magazine, and television advertisements,
3 as patients became 
more involved in their healthcare decisions.
4 Companies choose to advertise directly to 
consumers for many reasons, such as to trigger them to visit their physicians for previously 
untreated conditions, to accelerate transitions to newer drugs by making consumers aware of 
such new pharmaceuticals, and to create and maintain brand loyalty.
5 
There are three types of drug advertisements targeted directly to consumers.
6 There are 
health-seeking advertisements which educate consumers about a certain disease or condition 
without mentioning a specific drug.
7 There are also reminder advertisements which name a drug 
but provide no information on use, efficacy, or risks.
8 These two types of advertisements do not 
need to meet most of the requirements of FDA regulations on advertisements, such as the brief 
summary and fair balance, because they do not discuss the efficacy of the drug.
9 The third 
category is the product-specific advertisement, which is the most common type of DTC 
advertisement.
10 These advertisements promote a certain drug, describe its use, and present 
                                                         
1 Lars Noah, Advertising Prescription Drugs to Consumers: Assessing the Regulatory and Liability Issues, 32 Ga. L. 
Rev. 141, 141 (1997).   
2 Francis B. Palumbo and C. Daniel Mullins, The Development of Direct-to-Consumer Prescription Drug 
Advertising Regulation, 57 Food & Drug L.J. 423, 424 (2002). 
3 Lars, supra note 1, at 141.  
4 Palumbo, supra note 2.  
5 Lars, supra note 1, at 150.   
6 Michael S. Wilkes et al., Direct-to-Consumer Prescription Drug Advertising: Trends, Impacts, and Implications, 
19: 2 Health Affairs 110, 114 (2000). 
7 Id.  
8 Id. 
9 Palumbo, supra note 2, at 429. 
10 Wilkes et al, supra note 6. 2 
 
information on safety and effectiveness.
11 The discussion in this paper addresses this third type 
of DTC advertisements. 
The FDA has had authority over prescription drug promotional material since the passage 
of the Kefauver-Harris amendments in 1962.
12 The regulations promulgated at this time 
addressed promotions directed to medical professionals,
13 which was appropriate given the 
paternalistic nature of the doctor-patient relationship at this time.
14 In 1981, pharmaceutical 
companies proposed advertising directly to consumers, advocating increased public access to 
knowledge about drugs.
15 At this time, there was also a general trend in the political climate of 
increasing consumer sovereignty and empowering individuals with the ability to participate in 
their healthcare decisions.
16 The FDA requested a voluntary moratorium on such advertising to 
further analyze the issue.
17 In 1985, following the completion of several studies analyzing DTC 
advertising, the FDA lifted the moratorium.
18 The FDA requested that pharmaceutical 
manufacturers submit their DTC ads for preliminary comments.
19 
The FDA allowed for direct advertising, but only if the manufacturers abided by the 
existing regulations.
20 This included the “brief summary,” still seen in the current regulations, 
which required a true statement of information of side effects, contraindications, and 
                                                         
11 Wilkes et al, supra note 6. 
12 Palumbo., supra note 2, at 426. The 1962 amendments transferred regulatory authority over prescription drug 
advertising from the FTC to the FDA while authority over the advertising of over-the-counter drugs remained with 
the FTC. At this time, Congress was mostly concerned with advertising to medical professionals, and it is unlikely 
that there was the intent to have DTC advertising of prescription drugs under the FDA’s jurisdiction. Id. at 426-27. 
13 Lars, supra note 1, at 142.   
14 Wilkes et al., supra note 6, at 113. 
15 Id. 
16 Id. 
17 Lars, supra note 1, at 147-48.   
18 Michie Hunt, Direct-to-Consumer Advertising of Prescription Drugs, National Health Policy Forum, April 1998. 
Most of the studies concluded that consumers wanted more information on prescription drugs, and that consumers 
would tend to view such direct advertising as favorable. An FDA-commissioned study further concluded that risk 
and benefit information could both be conveyed through such direct advertising, in both print and broadcast form. Id. 
at 3. 
19 Wilkes et al., supra note 6, at 113. 
20Id. 3 
 
effectiveness of the advertised drug.
21 The industry argued that this requirement resulted in 
lengthy paper advertisements which consumers would not read, and that this practically 
prevented the use of broadcast advertisements.
22 In response, the FDA published the Consumer-
Directed Broadcast Advertisements Guidance in 1997, which addressed requirements for DTC 
advertising to the industry.
23 For broadcast advertisements, only major side effects and 
contraindications must be presented as long as there is adequate provision for dissemination of 
labeling in connection with the presentation.
24 The adequate provision requirement can be met by 
providing a toll-free number, an Internet website, a recommendation to ask a physician or 
pharmacist for more information, and a reference to a print advertisement or brochures in a 
publicly accessible place.
25 The combination of more aggressive marketing by manufacturers and 
the FDA’s acceptance of this type of advertising in hopes for a more educated patient population 
have led to the increased use of DTC advertising since the issuing of the Draft Guidance.
26 
Current regulations do not require FDA approval of advertisements prior to dissemination, 
except in certain situations.
27 Manufacturers may submit advertisements to the FDA prior to 
publication for comment.
28 The information in the advertisement must present a “fair balance” 
between information relating to side effects and contraindications and information relating to 
                                                         
21 21 C.F.R. Section 202.1. 
22 Wilkes et al., supra note 6, at 113-14. See, also, Hunt, supra note 18, at 4 (Manufacturers often resorted to the 
other two types of advertisements, reminder and health-seeking ads, to avoid the strict regulations. However, this 
could also backfire. FDA ordered removal of an ad of a woman “windsurfing” through a wheat field because 
consumers could usually figure out that Allegra, the drug that the manufacturer was implicitly advertising, was used 
to treat allergies.). 
23 US Food and Drug Administration, Patient and Physician Attitudes and Behaviors Associated With DTC 
Promotion of Prescription Drugs- Summary of FDA Survey Research Results (2004).  
24 21 C.F.R. Section 202.1. 
25 Division of Drug Marketing, Advertising, and Communications FDA, Guidance for Industry: Consumer-Directed 
Broadcast Advertisements (1997). 
26 Wilkes et al., supra note 6. 
27 21 C.F.R. Section 202.1.  
28 Id. 4 
 
effectiveness.
29 Advertisements that are false, lacking in fair balance, or otherwise misleading 
lead to a drug being misbranded.
30  This includes the use of any pictorial or graphic matter that is 
misleading in any way.
31 Due to the audiovisual nature of television commercials, advertisers 
may have an advertisement that does not violate the FDA regulations at first glance, but could be 
found to be misleading because of contradictory messages between the audio and visual 
components which minimize risk information compared to benefit information.
32 When the FDA 
identifies a violation, it sends a regulatory letter asking the manufacturer to cease dissemination 
of the advertisement.
33 
Proponents argue that direct-to-consumer advertising informs consumers of their choices 
and allows them to participate more meaningfully in their medical decisions.
34 The 
advertisements can make patients aware of underlying conditions, and can act as a springboard to 
a thorough medical examination with a physician.
35 Some studies have shown that patients report 
greater involvement in medical decisions and better compliance with their treatment regimens, 
suggesting there has been a positive impact of DTC advertising.
36 There are also suggestions that 
DTC advertising will decrease drug costs.
37 If there are competitors, advertising can reduce costs 
by promoting competition between different brands of drugs.
38  
Critics of direct-to-consumer advertising argue that these promotions play on consumer 
vanity or insecurity to increase demand, suggesting there will be more inappropriate use of 
                                                         
29 Id. 
30 Id. 
31 Id. 
32 Kelly N. Reeves, Direct-to-Consumer Broadcast Advertising; Empowering the Consumer or Manipulating a 
Vulnerable Population?, 53 Food & Drug L.J. 661,  674 (1998). 
33 Martin T. Gahart et al., Examining The FDA’s Oversight Of Direct-To-Consumer Advertising, 3 Health Affairs 
120 (2003). 
34 Lars, supra note 1, at 177-78.   
35 Wilkes et al, supra note 6, at 123. 
36 Balaji Datti and Mary W. Carter, The Effect of Direct-to-Consumer Advertising on Prescription Drug Use by 
Older Adults, 23:1 Drugs Aging 71, 72 (2006).  
37 FDA, supra note 23. 
38 Wilkes et al, supra note 6, at 122. 5 
 
medical treatment.
39 A report by the United States General Accounting Office found that sales of 
drugs with the highest DTC spending have risen more quickly than the sales of other drugs.
40 
The rise in sales was due to increased utilization rather than price increases, suggesting that DTC 
advertisements have led to increased use of prescription drugs.
41  
Critics also predict that DTC advertising will increase costs of treatment.
42 Although 
advertising may reduce prices in other industries, this is unlikely to occur with prescription drugs 
because prices are not usually presented in a DTC advertisement and higher prices may not 
reduce demand because consumers often have health insurance plans which pay for their 
medications.
43 Furthermore, DTC advertising is often used for driving sales of newer, more 
expensive products for symptomatic relief of chronic conditions, which carry huge market 
potential.
44 These drugs are often still covered by patent protection, and therefore can retain 
premium prices.
45 High prices combined with greater utilization rates can lead to a massive 
increase in total healthcare costs. 
There is also an inherent conflict between the goal of empowering consumers in their 
medical decisions and the promotional interests of the pharmaceutical industry, as a desire for 
increased sales for a particular drug may aligh with rational prescribing of treatments for 
patients.
46 It may be contradictory to require that these drugs be prescribed through a medical 
professional who has expert knowledge, yet allow marketing to consumers who lack that 
                                                         
39 Lars, supra note 1, at 169-70.   
40 United States General Accounting Office, Prescription Drugs: FDA Oversight of Direct-to-Consumer Advertising 
Has Limitations, GAO-03-177 (2002). 
41 Id. 
42 FDA, supra note 23. 
43 Wilkes et al, supra note 6, at 122. 
44 Matthew F. Hollon, Direct-to-Consumer Advertising; A Haphazard Approach to Health Promotion, 293 JAMA 
2030, 2030 (2005). See, also, USGAO, supra note 40 (All of the top 15 DTC-advertised drugs in 2000 were for 
chronic conditions, such as allergy/asthma, high cholesterol, and arthritis, and all but 1 of the top 50 drugs were for 
non-episodic conditions). 
45 USGAO, supra note 40.   
46 Wilkes et al, supra note 6, at 113. 6 
 
expertise.
47 Furthermore, the optimal treatment for a medical condition often includes non-
medical interventions such as stress management or diet and exercise.
48 A DTC advertisement 
stressing the use of a particular drug for that condition could interfere with the patient’s 
willingness to accept a physician’s comprehensive treatment plan.
49 
There is also serious doubt as to whether DTC advertisements really can educate about a 
particular condition.
50 One study of existing advertisements found that although most 
advertisements gave the name of a drug and symptoms of a condition, few identified a cause or 
risk factor of the condition, described prevalence information, or clarified any misconceptions.
51 
The majority of advertisements did not acknowledge any other alternative therapies, medical or 
non-medical.
52 If the educational quality of these advertisements is highly variable, this weakens 
one of the primary arguments of DTC proponents. 
In 2004, FDA published results from two patient surveys and one physician survey which 
analyzed the effects of DTC advertising on healthcare, from both a public health and doctor-
patient perspective.
53 Although DTC advertising seemed to increase patient awareness of health 
and treatment, there was no evidence of increased visits as a result of this advertising.
54 The 
report suggests that the usefulness of the “brief summary” is hampered by the technicality of the 
language, and proposes that the information should be presented in more consumer friendly 
formats and language.
55 About half of the physicians surveyed reported feeling at least a little 
pressure to prescribe specific drugs when requested by their patient who had seen a DTC 
                                                         
47 Id. at 116. 
48 Id. at 121. 
49 Id.  
50 Id. at 116. 
51 Dominick L, Frosch et al., Creating Demand for Prescription Drugs: A Content Analysis of Television Direct-to-
Consumer Advertising, 5 Annals of Family Medicine 1 (2007). 
52 Id. 
53 FDA, supra note 23.  
54 Id. 
55 Id. 7 
 
advertisement.
56 Both patients and physicians thought that DTC advertisements overstated drug 
efficacy and did not present a fair balance of benefits and risks of drugs, and fewer patients in the 
2002 survey, compared to the 1999 survey, indicated that DTC advertisements were helpful in 
their interactions with their physicians.
57 Although the results suggest that while patients believe 
they are skeptical of DTC advertisements, physicians believe that their patients are still being 
misled or confused by them.
58 Ultimately, the report concluded that there were both positive and 
negative effects of DTC advertising on public health and the doctor-patient interaction, and 
invited further research on the topic without issuing an opinion on whether regulation in the area 
should be tightened or loosened.
59 
There has been much criticism on the FDA’s actions concerning DTC advertising.
60 
Despite increased use of resources by manufacturers on DTC advertising, the number of 
regulatory actions fell dramatically during the period from 1997 to 2006.
61 This was likely a 
result of weakened FDA capacity to enforce advertising regulations.
62 For example, although 
spending on DTC advertisements increased by 45% between 2002 and 2004, the number of FDA 
staff members reviewing these advertisements only increased from three to four in the same 
period.
63 Furthermore, the proportion of broadcast advertisements that were approved by FDA 
prior to airing declined from 64% in 1999 to 32% in 2004.
64 Manufacturers who voluntarily 
                                                         
56 Id. 
57 Id. 
58 Id. 
59 Id. 
60 Julie M. Donahue et al., A Decade of Direct-to-Consumer Advertising of Prescription Drugs, 357 N. Engl. J. Med. 
673, 674 (2007).  
61 Id. at 679. 
62 Id.  
63 Id. 
64 Id. 8 
 
submit their advertisements for pre-dissemination approval could face delayed review, which 
discourages them from submission.
65  
The speed of enforcement action has also greatly declined.
66 A regulation issued in 2002 
requires that the FDA’s Office of Chief Counsel review and approve all regulatory letters.
67 Prior 
to this regulation, FDA officials reported that regulatory letters were issued within several days 
of the receipt of a misleading advertisement.
68 In contrast, the OCC’s goal in reviewing draft 
regulatory letters is within 45 working days, which does not include any time that the 
Department of Health and Human Services takes to revise the letter at the order of the OCC.
69  
This delay in enforcement action can lead to misleading advertisements completing their 
broadcast life cycle before such regulatory letters are even issued.
70 One-fifth of DTC 
advertisements air for only a month, and one-third air for two months or less.
71 For five draft 
letters submitted by the DDMAC between January and September of 2002, the number of days 
between submission and issuance ranged from 13 to 78 calendar days.
72 Although it is unknown 
whether DTC advertisements for those specific drugs had a short airing period, it is clearly 
possible for regulatory letters to reach manufacturers after their misleading advertisements had 
been aired for a significant period of time.
73 
The breadth and timing of FDA review may also lead to problems. The FDA targets its 
reviews to the advertisements that receive the greatest exposure,
74 which may lead to less-
                                                         
65 Id. at 679-80. 
66 USGAO, supra note 40. 
67 Id. 
68 Id. 
69 Id. The HHS has responded that the purpose of requiring OCC approval was to ensure that regulatory letters had a 
solid legal foundation in order to promote compliance. However, FDA regulatory letters issued prior to this 
regulatory had already been successful in ceasing dissemination of the identified misleading advertisements. Id. 
70 Id. 
71 Id. 
72 Id. The five letters were issued 13, 22, 39, 55, and 78 days after submission. Id. 
73 Id. 
74 Id. 9 
 
disseminated advertisements falling through the cracks. Furthermore, since companies submit 
advertisements for comments when they begin dissemination, the FDA cannot prevent 
misleading advertisements from reaching the public. Even if the FDA could adequately review 
all of the submitted advertisements, it is limited in its ability to police advertisements which were 
not submitted.
75 As of the USGAO report in 2002, the FDA contracted with a commercial 
service to monitor pharmaceutical advertisements that were broadcast on television.
76 The 
service, however, only monitored the six major cable television networks, the New York City 
affiliates of the four major networks, and PBS.
77 This could miss smaller cable television 
networks and local markets, which could lead to misleading advertisements remaining for long 
periods of time in certain locations.
78 
There is also no requirement that a drug be on the market for a certain amount of time 
before DTC advertising can commence. DTC advertisements often start after a drug has been on 
the market for only a year, so there is potential of wide dissemination of drugs with unknown 
long-term safety profiles.
79 
Another criticism of FDA enforcement is the lack of use of harsher remedies, such as 
seizing drugs for which there have been misleading advertisements or directing a company to run 
corrective campaigns.
80 Although FDA officials have stated that they have not resorted to such 
measures because companies have generally complied with their regulatory letters and the FDA 
does not want to remove beneficial drugs from the market, there have been repeat offenders who 
have received multiple regulatory letters for different advertisements promoting the same drug.
81 
                                                         
75 Id. 
76 Id. 
77 Id. 
78 Id. As an example, a misleading advertising was broadcast in Puerto Rico for 2 years. Id. 
79 Donahue et al, supra note 60 at 678-79. 
80 Gahart et al, supra note 33, at 121. 
81 Id. at 122. 10 
 
This suggests that FDA enforcement is not providing adequate deterrence, even for those 
companies who have actually been the target of enforcement actions.
82 
DTC advertising continues to be a controversial subject, especially with what some feel is 
a lack of policing by the FDA. 
 
II. DTC Advertising and Alzheimer’s Disease   
  Alzheimer’s disease is the most common cause of dementia, affecting one out of eight 
Americans over the age of 65, and leads to debilitation of cognitive and motor function and, 
eventually, death.
83 It is the sixth leading cause of death and has a slow, insidious progression 
with survival after diagnosis averaging four to eight years, but ranging up to twenty years.
84 
Secondary diseases such as depression and anxiety also often result upon diagnosis.
85 Symptoms 
commonly begin with mild cognitive impairment, such as patchy memory loss and subtle 
behavioral changes.
86 This progresses to moderate impairment with agitation and combativeness, 
and possible delusions and hallucinations.
87 Severe impairment is characterized by inability to 
speak or comprehend language and complete dependence on others to complete basic life 
functions.
88  
With the exception of certain rare, inherited forms of the disease, the exact physiologic 
changes in the brain that lead to Alzheimer’s remain unknown.
89 Diagnosis is made by the 
                                                         
82 Id. For example, the FDA issued four letters to Glaxo Wallcome for its advertising of the allergy drug Flonase in 
1999 and 2000, and four letters to Pfizer in a span of four years for its advertising of Lipitor. Id. 
83 Alzheimer's Association. 2012 Alzheimer's disease facts and figures, 8 Alzheimer's and Dementia: The Journal of 
the Alzheimer's Association 131 (2012). 
84 Id. 
85 Anna A. Theodorou et al., Drug Utilization Patterns in Patients With Alzheimer’s Disease, 2 The American 
Journal of Pharmacy Benefits 77 (2010). 
86 Philip D. Sloane et al., The Public Health Impact of Alzheimer’s Disease, 2000-2050: Potential Implication of 
Treatment Advances, 23 Annu. Rev. Public Health 213, 213 (2002). 
87 Theodorou et al., supra note 85, at 80. 
88 Sloane et al, supra note 86 at 213; Theodorou et al., supra note 85, at 80. 
89 Alzheimer's Association, supra note 83. 11 
 
physician through a combination of medical and family history and various cognitive tests and 
neurologic examinations,
90 but there is no definitive diagnostic test.
91 Input from a family 
member or another individual close to the patient can be very important in tracing cognitive and 
behavioral changes.
92 Although the cause or causes of Alzheimer’s disease are not yet known, 
there is general agreement that there are multiple factors involved, with interaction between 
genes and the environment.
93 Connections have also been suggested between lifestyle and 
Alzheimer’s disease.
94   
There are currently only five FDA-approved drugs and these drugs only treat the 
symptoms of the disease.
95 Drug efficacy is often short-lived, usually lasting from a few months 
to a few years.
96 However, active medical management can significantly improve quality of life 
for patients and their caregivers.
97 There is also ongoing research on alternative methods of 
treatment, such as music therapy.
98 
The FDA-approved drugs fall into two categories: acetylcholinesterase inhibitors and 
NMDA receptor antagonists.
99 The four approved cholinergic drugs, Donepezil, Rivastigmine, 
                                                         
90 Id. 
91 Sloane et al., supra note 86, at 215. 
92 Alzheimer's Association, supra note 83. 
93 Mark P. Mattson, Pathways Towards and Away from Alzheimer’s Disease, 430 Nature 631, 631-33 (2004). 
Alzheimer’s disease is characterized by destruction of neurons and degeneration of synapses between neurons. 
Definitive diagnosis requires postmortem examination of the brain and the presence of “plaques” and “tangles.” 
These are mainly found in the brain regions involved in memory and emotion. Cellular abnormalities result in the 
formation of these plaques and tangles, and many genes involved in these cellular abnormalities may be linked to 
susceptibility to Alzheimer’s disease. Other risk factors may be a low education level and history of head trauma Id. 
94 Id. at 633. Epidemiological studies have associated high-calorie and high-fat diets and a sedentary lifestyle with 
an increased risk of Alzheimer’s disease. A link with high cholesterol levels has also been suggested. Exercise may 
also provide neuroprotective effects.  Id. 
95 Alzheimer's Association, supra note 83. 
96 Theodorou et al., supra note_ at 78. 
97 Alzheimer's Association, supra note 83. 
98 Javier Olazarán et al., Nonpharmacological Therapies in Alzheimer’s Disease: A Systematic Review of Efficacy, 
30 Dement Geriatr Cogn Disord 161 (2010). Other nonpharmacological therapies include cognitive training, 
reminiscence, light therapy, and muscle relaxation. Therapies for caregivers include education, support, and respite 
care. Id. 
99 Francesca Mangialasche, et al., Alzheimer’s Disease: Clinical Trials and Drug Development, 9 Lancet Neurol. 
702, 703 (2010). 12 
 
Galantamine, and Tacrine,
100 most likely work by mitigating the decrease in the neurotransmitter 
acetylcholine in the brains of Alzheimer’s disease patients.
101 These drugs can improve cognition, 
behavior, and functional and global clinical state.
102 However, since they can only maintain 
neurotransmitter levels, and cannot prevent destruction of the neurons producing 
neurotransmitters, their effectiveness may drop as the disease progresses.
103 Galantamine and 
Rivastigmine are approved for treating symptoms in mild to moderate Alzheimer’s disease, 
while Donepezil is approved for all stages.
104 Memantine is the only approved non-cholinergic 
drug.
105 It works through a completely different mechanism: regulating levels of glutamate, 
another neurotransmitter.
106 Memantine can reduce clinical deterioration in moderate-to-severe 
Alzheimer’s disease.
107 Since the cholinergic drugs and Memantine work through different 
mechanisms, both a cholinergic drug and Memantine can be prescribed together.
108 Other 
pharmacological strategies include the use of nonsteroidal agents such as aspirin or ibuprofen to 
                                                         
100 NIH Publication No. 08-3431, Alzheimer's Disease Medications Fact Sheet, (2008, updated 2010), available at 
http://www.nia.nih.gov/sites/default/files/ADMedsFS.pdf. Tacrine is rarely prescribed now because of safety 
concerns. Id. 
101 Mangialasche, supra note 99, at 702. One characteristic of Alzheimer’s diseases is the early loss of basal 
forebrain cholinergic neurons, which normally produce the neurotransmitter acetylcholine. Acetylcholinesterase is 
an enzyme which breaks down acetylcholine released by neurons. The cholinergic drugs function by inhibiting 
acetylcholinesterase, which results in slower breakdown of acetylcholine, which thus helps mitigate the decreased 
release of acetylcholine. Id. 
102 Id.at 703. 
103 NIH Fact Sheet, supra note 100. 
104 Id. 
105 Mangialasche, supra note 99 at 702. 
106 Jon W Johnson and Shawn E Kotermanski, Mechanism of action of memantine, 6 Current Opinion in 
Pharmacology 61 (2006). Alzheimer’s disease is also characterized by deficits in glutamatergic neurotransmission. 
There have been several explanations for the cognitive benefits of Memantine, including reducing noise from 
excessive neurotransmitter receptor activation, inhibition of beta-amyloid toxicity, and readjustment of the balance 
between inhibition and activation of neurons. Id. 
107 Barry Reisberg et al., Memantine in Moderate-to-Severe Alzheimer’s Disease, 348 N. Engl. J. Med. 1333 (2003). 
The study reported greater tolerability of Memantine compared to the gastrointestinal side effect profile of 
cholinergic drugs, and emphasized alleviation of symptoms in patients with moderate-to-severe Alzheimer’s disease, 
with a lower average Mini-Mental State Examination base line score than that used in the donepezil study on 
moderate-to-severe Alzheimer’s disease. Id. 
108 NIH Fact Sheet, supra note 100. 13 
 
reduce inflammatory responses, enhancing putative protective factors through supplements such 
as vitamin E, and treating concomitant cardiovascular risk factors, such as hypertension.
109 
Research on Alzheimer’s disease has not come up with any disease-modifying drugs yet, 
although there are many ongoing clinical and experimental studies.
110 Developing effective drugs 
is especially difficult because of the complexity of the disease and lack of knowledge about its 
causes and mechanism of action.
111 There are likely several levels of interaction (between genes, 
proteins, cells, etc.) and multi-targeted therapies may be the most effective.
112  
  The impact of Alzheimer’s disease extends beyond the patient. Over fifteen million 
Americans provide unpaid care for an individual with dementia, mostly for family members.
113 
The sum of reimbursable, non-reimbursable, and unpaid labor costs in caring for an elderly 
patient at home may be as expensive as nursing home care.
114 Many of these caregivers report 
high levels of emotional stress and depression from providing care to their loved ones.
115 
Research also shows that this stress can lead to deterioration in physical health, including 
development of metabolic syndrome and increased risk of cardiovascular diseases.
116 Treatments 
for Alzheimer’s disease can therefore significantly reduce costs not only for patients but also for 
their families.  
                                                         
109 Sloane et al, supra note 86, at 217. 
110 Mangialasche, supra note 99 at 712. 
111 Id. 
112 Id. Multi-target therapies could involve prescription of several individual drugs, combinations of active 
ingredients in one drug, or designing of a single compound that has effects on multiple Alzheimer’s disease-related 
mechanisms. Id. 
113 Alzheimer's Association, supra note 83. 
114 Jennifer J. Dunkin and Cay Anderson-Hanley, Dementia Caregiver Burden: A Review of the Literature and 
Guidelines for Assessment and Intervention, 51 Neurology 53 (1998). 
115 Alzheimer's Association, supra note 83. See, also, Leah D. Clyburn et al., Predicting Caregiver Burden and 
Depression in Alzheimer’s Disease, 55B Journal of Gerentology S2 (2000) (Many studies have found caregivers are 
at a greatly increased risk of depression).  
116 Alzheimer's Association, supra note 83. 14 
 
  The global burden of Alzheimer’s disease is expected to increase dramatically in the next 
few decades as the world population ages.
117 One model predicts that the prevalence of the 
disease will quadruple from 26.6 million persons affected worldwide in 2006 to 106.2 million by 
2050.
118 Another study predicted that without any major therapeutic advances, 10.2 million 
persons will have the disease in the U.S. in 2050.
119 In 1995, a mid-range estimate of the total 
cost of Alzheimer’s disease care was $38,000 per patient per year, or $65 billion nationally.
120 
This will increase proportionately to the increased prevalence by 2050. The significance of any 
breakthrough in treatment is shown by an estimate that a six-month delay in disease onset would 
save approximately $18 billion annually after fifty years.
121 
  Alzheimer’s disease is an issue of significance for the FDA. In 2007, the Commissioner 
of the FDA made a statement about the FDA’s role in development of treatment for Alzheimer’s 
disease in front of a Senate subcommittee on Retirement Security and Aging.
122 With the 
increasing prevalence of the disease and the aging population, the FDA recognized Alzheimer’s 
as a disease that may cause great burdens on the American health system in the future.
123 Despite 
advancements in research on potential causes of the disease, many researchers emphasize the 
complexity of the disease and the necessity of approaching treatment possibilities from multiple 
directions.
124 The FDA is currently engaged in many projects that involve research and treatment 
of Alzheimer’s disease. This includes the Patient Representative Program, which will provide 
                                                         
117 Ron Brookmeyer et al., Forecasting the Global Burden of Alzheimer’s Disease, 3 Alzheimer’s & Dementia 186 
(2007). 
118 Id. at 190. 
119 Sloane et al., supra note 86, at 224. 
120 Id. at 217. 
121 Id. 
122 Statement of Andrew C. von Eschenbach, 2007, available at 
http://www.fda.gov/NewsEvents/Testimony/ucm110879.htm 
123 Id. 
124 Id. 15 
 
patient and caregiver insight into regulations on the disease.
125 Specifically, to address the 
problem of diminishing intellectual function of patients with the disease, the FDA has agreed to 
include patient and caregiver couples in the program so that caregiver insight can continue even 
after the patient can no longer participate due to the debilitating nature of the disease.
126 
Furthermore, the FDA has a Neurology Working Group and is engaged in a study with the NIH 
in acquiring information about Alzheimer’s.
127 The FDA is therefore heavily involved in 
research on Alzheimer’s disease and the potential impact of the disease on the American public. 
The influence of DTC advertising on Alzheimer’s disease patients and their families should be 
an issue of interest for the FDA given their involvement in researching the disease and its 
treatment. 
There are many reasons that drug manufacturers advertise Alzheimer’s drugs directly to 
consumers. DTC advertisers are likely to develop drugs that have only been marginally treatable 
or untreatable until recently, like Alzheimer’s disease.
128 These drugs often can be sold at 
premium prices because of patent protection.
129 Furthermore, given that the majority of ads 
promote drugs that maintain chronic conditions, Alzheimer’s is a lucrative target because of its 
prolonged progression and incurability.
130 The policy issues that address such “breakthrough” 
drugs are especially difficult because these drugs are often medically warranted and lack 
therapeutic alternatives.
131 Manufacturers may be able to charge a higher price and consumers 
may demand the drug once they are informed about it through advertising.
132 Although the drug 
may be beneficial, there is the societal cost from the pressure exerted on physicians and insurers 
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from dissemination of knowledge of the drug by DTC advertising.
133 These problems are likely 
to be especially pronounced for treatments of Alzheimer’s disease given the relatively low 
number of available drugs. 
Advertising for Alzheimer’s disease drugs, as for many other prescription drugs, is 
targeted towards older adults in the American population. Given the tremendous costs of 
healthcare and the projected prevalence of Alzheimer’s disease, any effect on healthcare as a 
result of DTC advertising could significantly affect medical costs in the U.S. A relatively recent 
study by Datti et al. on the effect of DTC advertising on older adults suggests a significant 
impact, although it is difficult to tell whether the increased costs are outweighed by the 
benefits.
134  The study found that although older adults are less likely than younger adults to 
request a specific drug following DTC advertising, older adults are more likely to be referred for 
additional medical services.
135 The study could not answer whether this increased referral rate 
was beneficial in that conditions could be diagnosed earlier or more effective therapy could be 
offered, or if it was harmful by encouraging expensive and unnecessary treatments.
136 The article 
also notes how new Medicare provisions that offer better compensation for medications for older 
adults could make patients more likely to request DTC drugs and therefore amplify the results in 
their study.
137 All of these results suggest that increased DTC advertising for Alzheimer’s disease 
has the potential of increasing use of healthcare services.  
Older adults are also more likely than their younger counterparts to believe they are not 
as affected by DTC advertising as others.
138 One study found that in general, consumers believe 
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DTC ads exert more influence on others than on themselves, and that this third-person effect was 
magnified for negative ad effects compared to positive effects.
139 A further study by the same 
group found that older adults may underestimate the effects on DTC advertising on 
themselves.
140 While the surveyed adults denied DTC ad effects on themselves, their answers on 
other questions showed that they exhibited DTC-ad-expected behaviors such as learning about 
drug benefits and risks, talking with friends and relatives, and searching for more information by 
talking to a doctor or using the Internet.
141 Influences of DTC advertising, including those for 
Alzheimer’s disease, are therefore likely to have more of a hidden impact on older adults than 
younger adults due to this misperception.  
  Another source of concern for DTC advertising for Alzheimer’s disease is the alternative 
target of marketing. As previously mentioned, the emotional and physical impact on caregivers 
of Alzheimer’s disease patients can itself result in a burden on public health. One study found 
that advertisements for the Alzheimer’s disease drug Aricept frequently appeared in magazines 
read most commonly by women in their forties.
142 Advertising of treatments for Alzheimer’s 
appeals not only to the patient suffering from the disease but also to the caregiver who is looking 
to improve the quality of life of his or her loved one, which indirectly improves the caregiver’s 
quality of life as well.  Although there is the potential of saved costs from both of these classes of 
individuals, there is also added vulnerability as caregivers are looking for any source of help for 
the patient. Since these drugs can only address the symptoms of Alzheimer’s disease and may 
not help an individual patient at all, the added stress from failed treatment for both the patient 
and caregiver could add to the costs of increased DTC advertising. 
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  The Datti article notes how DTC advertising targeted to individuals other than the 
patients could affect the results of their study.
143 Since older Alzheimer’s disease patients are 
targeted from multiple directions through DTC advertising, the results from the Datti study may 
be underestimated.
144 The Datti study only asked whether older adults requested specific drugs 
for their own care after personally being exposed to a DTC advertisement.
145 This excludes 
situations where another adult who accompanied the patient requested a drug, or a patient 
requested a drug at the suggestion of a family member who was exposed to a DTC advertisement. 
These situations may have also led to referrals or extra treatments. This means that the potential 
effects on healthcare costs from DTC advertisement could be much higher than what is predicted 
from the results in the Datti study, which is another reason for the urgency and importance of 
analyzing this issue in more detail.                                     
 
III. A Case Study: Aricept 
Aricept is the brand name for Donepezil, a cholinergic drug.
146 Aricept was approved by 
the FDA in 1996 and is manufactured by Eisai.
147 It is indicated for treatment of mild, moderate, 
and severe stages of Alzheimer’s disease.
148 This paper will analyze how Aricept is presented in 
its physician label, patient insert, and DTC television advertisements. 
The Aricept Physician Prescribing Information starts off with a “Highlights” section and 
then has the longer detailed prescribing information section.
149 The full prescribing information 
                                                         
143 Datti, supra note 36. 
144 Id. at 80. 
145 Id. at 73-74. 
146 Aricept Label, available at 
http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020690s035,021720s008,022568s005lbl.pdf 
147 Orange Book Detail Record Search for Aricept, Food & Drug Admin., available at 
http://www.accessdata.fda.gov/scripts/cder/ob/docs/obdetail.cfm?Appl_No=020690&TABLE1=OB_Rx. 
148 Aricept Label, supra note 146. 
149 Id. 19 
 
contains information on the dosage and administration of the drug, contraindications, warnings, 
adverse reactions, pharmacology and toxicology, and description of the clinical studies that 
showed efficacy of the drug.
150 For adverse reactions, the label includes tables of the rates of 
adverse events during the clinical trials for different dosages and comparisons between placebo 
and drug, along with written summaries of the results.
151 The effectiveness of Aricept is 
described both graphically and verbally in the Clinical Studies section, which summarizes the 
results from various studies using different doses of the drug and for different stages of the 
disease.
152  
The Patient Insert for Aricept includes similar information, but in easier language and in 
much shorter form. Most of the insert discusses complications of the drug and instructions on 
how to take it, rather than the benefits.
153 There is only one section on benefits and it uses careful 
language so as to not overstate its claims.
154 It says that the drug “can help” with mental function 
and daily tasks, and that it does not work the same in all people.
155 It gives four possibilities of 
the effects of the drug: patient gets “much better,” patient gets better in “small ways” or stays the 
same, patient gets worse at a slower pace, and patient gets worse as expected.
156 The insert states 
that the drug does not cure Alzheimer’s disease and that all patients with the disease get worse 
over time, even if they take Aricept.
157 The rest of the insert is devoted to general information, 
ingredients, instructions, and some of the negative effects of taking the drug.
158 The major 
contraindication is allergic reaction, and the insert lists health problems to discuss with a 
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physician before taking Aricept.
159 There is also a list of serious side effects, followed by a list of 
the most common side effects.
160 The insert seems to be a fair assessment of the risks involved 
with taking the drug without an overstatement of the benefits. The listing of the four categories 
of effects of the drug makes it clear that the drug can improve symptoms, but also that it may just 
slow down progression of the disease.  
The major difference between the physician label and the patient insert is the discussion 
of efficacy of the drug. While the patient insert simply lists four possible effects of the drug, the 
physician label introduces the results of the clinical studies. There is no information in the patient 
insert on the breakdown of which end result is more probable. There is also no information on 
symptoms of Alzheimer’s disease. This highlights the importance of a thorough medical 
examination by a physician in deciding whether a patient is a candidate for use of a drug and 
explanation to the patient of the probability of improvement or slowing down of progression of a 
disease, regardless of whether the patient came to the doctor because of exposure to DTC 
advertising. 
Two television advertisements for the drug have a clearly different approach and 
presentation of Aricept.
161 Both commercials are 60 seconds long and follow a similar structure. 
They start off with a person other than the patient talking to the viewer about when they became 
concerned about a loved one. One commercial is of a woman talking about her husband, and how 
he could not remember his granddaughter’s name when they picked her family up at an airport 
one day (this ad will be referred to as “Airport” from now on). The other commercial is, again, of 
a woman, but this time talking about how her mother forgot that her daughter’s family visits her 
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every week on Sunday (this will be referred to as “Sunday”). This anecdote-type opening 
continues for about 15 seconds, with images of the confused-looking patient.  
  Both commercials then turn to the speaker and the patient visiting a doctor together, 
where they hear about Aricept being the only drug that is available for all stages of Alzheimer’s 
disease. There is also a scene of a doctor showing the patient and family member an image of 
two nerve cells and small bubbles traveling from one nerve cell to the other. Some of the bubbles 
are popping, while others form a dark rim around them. The commercial then goes on to explain 
the benefits of Aricept, and how it can slow symptoms of Alzheimer’s disease and can improve 
cognition. A little after the 30 second mark, both commercials go into the warnings and potential 
side effects of Aricept. While the narrator (a voice different from the original speaker) describes 
these risks of the drug, the visual image is a scene of the patient enjoying time with his or her 
family and responding to family members. This is presumably after the patient has taken the drug. 
In the “Airport” ad, the patient is seen on a family excursion and later picking photos for an 
album, and the viewer can hear the patient point to one picture and say he likes that one. In the 
“Sunday” ad, the patient is seen making a bed and helping set a table for dinner with the family. 
In the last five seconds, the message to go see a doctor is reiterated along with the slogan “don’t 
wait, Alzheimer’s isn’t waiting.” 
  Using the analysis structure of the Frosch article on DTC television advertising,
162 the 
commercials have the common story structure of using “before and after” images of a patient. 
Both make factual claims about symptoms. However, neither really goes into the biological 
nature or mechanism of the disease. Although the seemingly scientific image of the two nerve 
cells is shown, there is no explanation as to what the bubbles in between the nerve cells are and 
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what, if any, effect the drug is having on either the nerve cells or the bubbles in between.
163 
There is nothing labeled in the picture besides “nerve cells.” There is no information on risk 
factors, prevalence, or subpopulations at risk of the condition.  
The appeals in the commercial are mostly positive and negative emotional appeals. 
Although there is some information about how the drug can improve function, they are done 
through the voice of the patient’s family member, which can be seen as more of a positive 
emotional appeal to the caregiver of a patient with Alzheimer’s disease. The lifestyle portrayals 
consist of showing how the disease interferes with the patient’s relations with family members 
and how the drug can improve the patient’s condition. There is no statement about alternative 
therapies to help with the condition. Finally, the commercials imply that Aricept is a medical 
breakthrough in that is the only drug approved for all stages of Alzheimer’s disease. 
  These advertisements follow the pattern of the majority of such DTC advertisements that 
were studied in the Frosch article.
164 For example, both Aricept ads and the majority of the ads in 
the Frosch article provided some factual information about the disease, such as symptoms, but 
neglected to provide information on risk factors or prevalence.
165 Furthermore, the 
advertisements almost always used positive emotional appeal and some negative emotional 
appeal.
166 Another similarity is the reference to the drug being a medical breakthrough of some 
sort (being the only product that treats all stages of Alzheimer’s disease), which was seen in 58% 
of the advertisements in the Frosch study.
167 
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 Given the similarity of the Aricept advertisements to those studied in the Frosch article, 
similar conclusions can be made about their potential impacts on viewers. First of all, the risk 
factors and symptoms of the disease are ambiguously defined, which can cause a large range of 
viewers to believe that treatment is necessary, even when they or their loved one does not have 
Alzheimer’s.
168 The limited information on the disease may be contributing to increased 
medicalization of the American population.
169 For example, decreased cognition could be a sign 
of Alzheimer’s, any other form of dementia, or just normal aging. The lack of clear information 
on what symptoms should be treated with Aricept will lead to a larger population of people 
believing that Aricept could be the solution to their problems than appropriate.  
Furthermore, the use of positive and negative emotional appeals may cause viewers to 
discount factual information about risks and benefits and to seek treatment for clinically 
inappropriate reasons such as fear from not using the product or expectations of happiness if they 
do use the product.
170 This problem is likely to be accentuated in the case of Alzheimer’s, 
because the commercial is directed to family members of patients as well as patients themselves. 
This is highlighted by the fact that the speakers of the two Aricept commercials are not the 
patients, but the patient’s wife in the “Airport” ad and the patient’s daughter in the “Sunday” ad.  
The two ads also followed the typical pattern of showing patients who lost control of 
their lives as a result of their condition and how they regained control after treatment.
171 These 
advertisements often do not portray the average benefit of drug use, and also make suggestions 
about the drug that others dispute.
172 Although the Aricept advertisements do not present that all 
patients will benefit as the patients in the commercials have, they also do not describe the typical 
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pattern of improvement or the possibility of the drug just slowing down progression of the 
disease. In these ways, DTC advertisements can distort and inflate expectations about the impact 
of the drugs on a condition.
173 The Aricept advertisements can give a false expectation that 
cognition and activity will return to normal, or at least improve, when it is probable that patients’ 
Alzheimer’s disease may just deteriorate at a slower pace. 
The main differences between the patient insert and television advertisements relate to 
the balance between the positive and negative aspects of the drug. While the patient insert only 
has a brief section on benefits and outlines all potential effects of the drug, including no change, 
the television advertisement focuses at least half of its time on the before and after of a “best-
case” scenario where the patient’s condition actually improves. There is no discussion of the 
possibility that the drug will only slow progression. Furthermore, while most of the space for the 
patient insert discusses warnings and possible side effects, less than half of the television 
advertisement discusses such negative aspects of the drug. Lastly, even though the time devoted 
to factually describing the benefits of the drug may be comparable to the time devoted to 
describing risks and side effects, the visual images that are shown during the explanation of the 
risks and side effects are positive images of the patient getting better, which seem to further tip 
the balance of the advertisement towards the benefits. All of these are reasons that the television 
advertisement may give a more positive impression of the drug than the patient insert. 
  The FDA has taken actions against the manufacturer for two of its Aricept advertisements. 
The FDA sent a warning letter to Eisai Medical Research in 2010 stating that two Aricept 
television ads were misleading because they overstated the efficacy of the drug, thus leading to 
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Aricept being illegally misbranded.
174 The two commercials that the FDA found misleading are 
very similar in format to the two advertisements analyzed above, with the same pattern of a 
family member observing changes in the patient, the two of them visiting a doctor, and 
concluding with improvements in the patient’s function.
175 Many of the criticisms in the FDA 
letter therefore likely apply to the two advertisements analyzed in this paper.  
The letter focuses on the conjunction of the images of improved function and statements 
that Aricept can slow progression Alzheimer’s symptoms and can improve cognition.
176 The 
problem seems to be that the behavior of the patients in the advertisements “changes 
dramatically” after the visit to the doctor.
177 In one advertisement, an elderly man who starts off 
looking disinterested is later shown “happily interacting” with family.
178 In the other 
advertisement, an aloof and confused elderly woman is later shown working on a garden with her 
daughter and grandchildren.
179 This is very similar to the Airport and Sunday ads where the 
confused-looking elderly patients are later seen interacting with their families after visiting the 
doctor. The FDA letter states that these claims and presentations misleadingly overstate efficacy 
because they imply that Aricept treatment can restore patients’ cognitive and daily functioning to 
normal, when clinical trials do not support such a drastic improvement.
180 The FDA focuses on 
the visual images, rather than just the spoken parts, as it adds that including the superimposed 
text, “Individual results may vary,” does not “mitigate” the misleading quality of the 
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advertisements.
181 Finally, the FDA requests that Eisai immediately cease the named 
advertisements.
182 
  Although the FDA eventually did address problems with the Aricept advertisements, the 
warning letter came fourteen years after the approval of Aricept. Although the exact date that 
television advertising started is not clear, it is likely that such advertisements were on the air for 
several years before they were put to a stop. This suggests that enforcement actions, even when 
they do happen, do not come quickly enough to remove misleading advertisements from the 
public. Considering the scope of Alzheimer’s disease, having such a television advertisement out 
for several years may have misled millions of viewers about the effectiveness of treatment. 
  Continued dissemination of misleading advertisements on the air is also not good for the 
pharmaceutical companies. Although they may initially have more patients due to increased 
demand for the drug, such advertising can lead to negative publicity. A simple internet search for 
“Aricept commercial” leads to links for parodies of the typical Aricept television 
advertisement,
183 and a search for “Aricept television advertisement” leads to news articles about 
the enforcement action against Eisai/Pfizer.
184 This also shows that a good portion of the public 
knows about and is interested in the Aricept commercials, which again supports the proposition 
that the FDA did not act quickly enough in removing these advertisements from dissemination. 
  Aricept is an example of an Alzheimer’s disease drug which has been widely advertised 
through DTC advertising and has faced problems for its campaign. The effects of a misleading 
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advertisement can be very significant given the number of individuals affected by the disease and 
the number of their caregivers. 
 
IV. Next Steps and Proposals for Change 
  Although there are many studies on the increased use of DTC advertising and its impacts 
on patient and physician perceptions, there is a lack of evidence of the impact of DTC 
advertising for specific drugs or fields of drugs. Given the projected increased prevalence of 
Alzheimer’s disease, a study on the impact of DTC advertising on the usage of drugs to treat the 
disease and the overall costs and benefits of any changes in usage from such advertising may be 
beneficial. More specifically, studies similar to the Datti study could be conducted, but with a 
focus on whether Alzheimer’s disease DTC advertisements affect the likelihood of increased 
drug prescription or the use of medical services in the older adult population. Furthermore, given 
the extra target of Alzheimer’s DTC ads, a similar study could analyze the effects of the ads on 
family members requesting drugs or treatment on behalf of affected individuals, and whether this 
increases healthcare costs. A cost-benefit analysis is likely to be much more difficult, as it is 
challenging to assess psychological and other non-economic benefits from increased quality of 
life as a result of Alzheimer’s disease treatment, but interviews of patients and caregivers could 
assess their satisfaction with pharmaceutical treatment and the rate at which they were 
dissatisfied by results due to high expectations from seeing DTC advertisements. 
There are also many possibilities of reform for various sectors regarding DTC advertising 
in general and specifically for Alzheimer’s disease. Given that prohibiting pharmaceutical 
advertising would likely be a violation of the First Amendment, most proposals for reform are 28 
 
aimed at tighter regulation of DTC advertising by the FDA.
185 This includes development of 
more comprehensive standards, and an increase in funding so that the FDA can adequately 
review and enforce these standards.
186 Review of advertisements should focus especially on the 
visual elements, rather than on just the written or printed information.
187 As seen in the Aricept 
example, the visual portions of a television advertisement may mislead the audience. Even if 
they are not misleading, the visual images are often one-sided, and can upset the “fair balance” 
of the audio or spoken portions of the advertisement. Although it may not be practical to force 
manufacturers to visually show negative effects of a drug, more than half of the spoken part of a 
commercial could be devoted to risks to off-set the visual elements which are solely devoted to 
benefits. 
Problems with DTC advertising often lie in the lack of information that the patient has, 
and there are other institutions which can support the FDA in providing more comprehensive 
information, such as the NIH and the AMA through its medicals schools and residencies.
188 
Suggestions have also been made to supplement manufacturer advertising with public service 
messages which recommend consultation with physicians for certain conditions without 
reference to any specific treatment plan.
189 Also, the FDA could impose a moratorium on 
advertisement for a set period of time or under certain situations, such as for the first three years 
after initial market release of a drug.
190 The FDA should also educate the public as to the roles of 
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promotional materials.
191 This will allow consumers to maintain a healthy skepticism towards 
DTC advertising. 
  These proposals can be shaped or adjusted depending on the type of drug being 
advertised. Given the special considerations of Alzheimer’s disease discussed above, there could 
be special regulations pertaining to advertisements directed at family members of patients rather 
than patients themselves. Furthermore, education efforts would have to be addressed to the 
family in addition to the individual patient. This could involve special training in medical 
education for consultation with family or public service messages addressed to family members. 
As for a moratorium, a longer period of prohibition of advertisements for treatments of 
Alzheimer’s disease may be appropriate than what is proposed above. This is because of the 
prolonged nature of both the disease and the recognition of any benefits from treatment.  
  Suggestions for reform have also been addressed to the pharmaceutical industry.
192 These 
include making advertisements more disease-centric than drug-centric, and encouraging 
nonproprietary partnerships with researchers to study the effects of DTC advertising and come 
up with strategies to more effectively communicate information to consumers.
193 Such changes 
would likely be helpful in the context of Alzheimer’s disease. Since effective management of the 
disease can rely on more than a single type of treatment, a disease-oriented advertisement could 
lead to more effective use of medical treatment within a comprehensive regimen. Although such 
advertisements may not directly lead to use of a specific drug to treat the disease, they could lead 
to greater awareness of the disease which may result in more patients using medication to treat 
their conditions. Furthermore, enhancing consumer knowledge about the actual effectiveness of 
drugs could prevent heightened expectations from drugs which could lead to negative publicity 
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or even litigation when a drug fails to meet those expectations. In these ways, the above 
mentioned reforms could even be helpful for manufacturers of Alzheimer’s disease drugs.  
   The medical community, which often voices many of the criticisms towards DTC 
advertising and pharmaceutical manufacturers, should also be involved in reforming the 
system.
194 Studies have shown that primary care physicians are often the most skeptical towards 
DTC advertising.
195 As mentioned above, the medical community should be involved in 
informing the patient about available drug and non-medical therapies for conditions, as well as 
educating the public on the appropriate uses and limitations of medication.
196 At individual visits, 
physicians should not forego a thorough medical examination and succumb to pressure to 
prescribe medications for new conditions that patients come with as a result of watching a DTC 
advertisement.
197 With respect to Alzheimer’s disease, there is a need to educate patients on the 
limits of the available drugs, especially since Alzheimer’s is an incurable disease. There should 
be explanations on how the situations reflected in television advertisements may be a “best case” 
scenario so that patients and their families have a realistic view of what to expect from treatment.  
  DTC advertisements are likely here to stay. The FDA should continue to monitor and 
review these advertisements, especially for new treatments, so that the costs of increased 
prescription and use of expensive drugs do not outweigh the medical and social benefits of these 
medical therapies. The industry should also be cautious in not overstating the benefits of 
treatments, not just because of potential enforcement action by the FDA but also for publicity 
reasons and to have a more knowledgeable consumer base. Finally, the medical community 
should continue to educate patients of the true risks and benefits of various therapies while not 
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ignoring patients who have brought a drug or condition to the attention of the physician because 
of a DTC advertisement. The number of cases of Alzheimer’s disease will continue to increase as 
the population of America ages. Although the available therapies can only mitigate symptoms or 
slow down progression of the disease, any improvement on quality of life for patients and their 
caregivers can have a significant effect on public health and societal costs. There are many 
problems with the current state of DTC advertising of Alzheimer’s disease drugs. However, 
abolition of such advertising is not necessarily the best solution in improving the health of the 
American public and economy. As long as the FDA effectively polices advertisements so that 
they do not overstate the benefits of such treatments, and patients and their families receive 
thorough and accurate information from a wide variety of sources, DTC advertising has the 
potential of bringing relief to millions of patients and caregivers whose lives are affected by 
Alzheimer’s disease.   